Compound | Multiple Dose (Steady-State) 3DAA Combo Regimena | ||
---|---|---|---|
Total AUCt | AUCtb | Cmax | |
% | ng⋅h/ml | ng/ml | |
Ombitasvir | 51.9 | 1745 | 125 |
M23 | 5.8 | 194 | 9 |
M29 | 19.9 | 669 | 31 |
M36 | 13.1 | 442 | 23 |
M37 | 9.3 | 312 | 16 |
AUCt, AUC (0–24h).
↵a 3DAAs regimen [paritaprevir/ritonavir (150/100 mg), ombitasvir (25 mg), and dasabuvir (400 mg twice daily)] was administered to healthy human subjects for 14 days.
↵b Pharmacokinetic samples were collected on day 14 up to 24 hours and pooled across the subjects for quantitative HPLC-MS/MS analysis.